Company ProfilePremium

Australian Pharmaceutical Industries Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Australian Pharmaceutical Industries Limited - Company showcase

Australian Pharmaceutical Industries Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Australian Pharmaceutical Industries Limited Overview

API continues to trade as Australian Pharmaceutical Industries Pty Ltd, the legal entity at the centre of the Wesfarmers Health division. It is the contracting party for subsequent acquisitions such as InstantScripts (Wesfarmers Health release, 12 June 2023) and the Infinity Pharmacy Group receivership (Priceline Pharmacy statement, December–January 2025/26).

  1. API as the operating entity.

  2. Wesfarmers Health as its reporting perimeter.

Where only parent-level data exist, the listed parent Wesfarmers Limited (ASX: WES) is used.

API is the operating backbone of Wesfarmers Health. It is one of Australia's three national full-line pharmaceutical wholesalers, alongside Sigma Healthcare and EBOS's Symbion, and it is also franchisor of Priceline Pharmacy, the country's largest health-and-beauty-focused pharmacy banner.

Since being absorbed by Wesfarmers in March 2022, it has evolved from a low-margin distributor with a retail arm into a multi-format health platform. The platform spans:

  • 433 franchised Priceline Pharmacies and 67 company-owned Priceline/atomica stores

  • 152 banner pharmacies (Soul Pattinson, Pharmacist Advice, Pharmacy 4 Less)

  • 180 medical-aesthetics clinics (SILK, Clear Skincare)

  • the InstantScripts telehealth platform

  • an automated fulfilment network serving over 4,000 pharmacy customers

Revenue reached A$6.47bn in FY2026, but margins remain thin: EBT margin was 1.2% and return on capital 4.2%. The investment case is therefore a margin-mix story. Management is shifting earnings toward the higher-margin Consumer business, using Wesfarmers' data, loyalty (OnePass, Pulse Rewards) and supply-chain capabilities, while defending wholesale share against a merged Sigma–Chemist Warehouse.


What the company does

API/Wesfarmers Health runs three interlocking activities.

1. Pharmaceutical wholesale (the "Wholesale" business).

API buys prescription (PBS-listed and private) medicines, over-the-counter (OTC) products, and health, beauty and general merchandise from manufacturers. It warehouses them in a national network of fulfilment centres and delivers to community pharmacies, often more than once daily. Customers include:

  • Priceline Pharmacy franchisees

  • banner-group members

  • independent pharmacies

  • other groups such as Pharmacy 777 in Western Australia (added around 2020–21, per API CEO remarks reported by Pharmacy Daily, January 2021)

  • hospitals and other channels

API participates in the Commonwealth's Community Service Obligation (CSO) arrangements for full-line wholesalers. These require it to supply the full PBS range to any pharmacy within set timeframes, in return for a share of a government funding pool. In FY2026, wholesale growth was driven by new customer acquisitions and demand for GLP-1 weight-loss and other high-value drugs, while automation lowered supply-chain unit costs (WES FY26 Results).

2. Consumer retail and franchising (the "Consumer" business).

Sources: WES FY26 Results; Pharmacy Daily, 19 August 2026.

3. Private-label and exclusive brands.

API has long developed owned and exclusive health, personal-care and beauty lines sold mainly through Priceline. In the listed era this was reported as "Consumer Brands", which grew revenue 30.7% in FY2019 (Pharmacy Daily, FY19 results coverage). Under Wesfarmers this has extended to AestheticsRX and "differentiated beauty, skincare and private label ranges" (WES FY26 Results).

Business and revenue model

Revenue streamNatureMargin profileDisclosure
Pharmaceutical wholesale salesProduct sales (PBS medicines, OTC, front-of-shop goods) to pharmacies; CSO fundingVery low gross margin; PBS mark-ups regulatedRevenue split not separately disclosed post-2022
Franchise fees, rebates and marketing leviesService/royalty-type income from Priceline Pharmacy franchiseesHigher margin—
Company store retail salesDirect retail (Priceline, atomica)Retail margin—
Clinic servicesLaser hair removal, skin treatments, injectables; service fees, memberships and packagesHigher margin—
Telehealth feesPer-consult or subscription digital health servicesHigher margin, asset-light—
Health station / data servicesSiSU stations; partner/sponsor revenue——
Retail mediaSupplier-funded advertising across Priceline digital and physical assetsHigher margin—

Independent characterisation. By revenue, API remains overwhelmingly a product distributor. In FY2021, before the takeover, pharmacy distribution was roughly three-quarters of revenue (Barchart company description; API FY2020 reporting cited by Pharmacy Daily put pharmacy distribution revenue at A$2.9bn of approx. A$4.0bn).

By earnings potential and management attention, however, the Consumer business is the centre of gravity. Wesfarmers repeatedly describes its aim as "growing share and scale in the higher-margin and less capital-intensive Consumer segment and improving performance in the Wholesale segment" (Wesfarmers FY25 commentary reported by Pharmacy Daily, August 2025).

The FY2026 divisional margin, an EBT margin of 1.2%, shows that the mix shift is still at an early stage.

Value-chain position

API sits in the middle of the Australian medicines value chain:

Manufacturers / importers → full-line wholesaler (API) → community pharmacy (franchised Priceline Pharmacy, banner and independent stores) → patient/consumer

It also has vertically integrated:

  • forward positions into retail brand ownership (Priceline), clinics (SILK/Clear Skincare) and digital prescribing (InstantScripts), and

  • backward positions into private-label product development.

Australian pharmacy ownership and location rules restrict pharmacy ownership to registered pharmacists. As a result, API and Wesfarmers cannot own dispensaries directly; Priceline Pharmacy operates through franchise agreements with pharmacist owners. Wesfarmers has publicly stated its support for these rules (Wesfarmers statements at the November 2021 Scheme Implementation Deed and the March 2022 completion).

Customer types and end-markets

Customer typeEnd-market
Community pharmacies (franchised, bannered, independent)Prescription medicines (PBS), OTC medicines
Retail consumersHealth, beauty, personal care, cosmetics, vitamins and supplements
Patients (direct-to-consumer)Telehealth consultations, e-prescriptions
Clinic clientsMedical aesthetics (laser, skin, injectables)
Suppliers / advertisersRetail media, loyalty-linked promotions
GovernmentCSO funding, vaccination and pharmacy services programs (indirectly via pharmacies)

Company's own description

Wesfarmers describes the division as a business that is "well positioned to continue improving earnings and returns by executing its transformation program and capitalising on trends in the large and growing health and beauty market" (WES FY26 Results, Health outlook).

At its 2023 formation review, Wesfarmers described the division as a "complementary portfolio of health, wellbeing and beauty assets that is well positioned to deliver long-term growth and capitalise on health sector tailwinds" (Wesfarmers 2023 Annual Report, as reported by Pharmacy Daily).

Strategy

Stated strategy themes (Wesfarmers FY2025–FY2026 releases, paraphrased)

  1. Execute a multi-year transformation program to improve earnings and returns. Wesfarmers describes this as "gaining momentum" in FY2026.

  2. Accelerate growth in the higher-margin Consumer business: Priceline network growth, value pricing on key lines, differentiated beauty/skincare/private label, digital and loyalty.

  3. Build on recent improvements in Wholesale: customer acquisition, automation of fulfilment centres, investment in core technology systems.

  4. Expand the addressable market through new formats: atomica, Pharmacy 4 Less, InstantScripts Pharmacy Health Hub.

  5. Leverage Group capabilities: OnePass, OneData (about 12m customer records), the OneReach retail media network, AI, and the Flybuys JV.

Strategic initiatives announced or executed in the last 24 months

InitiativeDateDescriptionStatus
atomica beauty formatJan 2025New affordable beauty retail chain10 stores at 30 June 2026
InstantScripts Pharmacy Health HubPilot from mid-2024; expanded FY2026Pharmacy format integrating telehealth4 stores at 30 June 2026
Pharmacy 4 Less acquisition4 Jun 2025Discount banner, 65 pharmaciesIntegrated; named FY27 growth format
Telehealth Code of PracticeJul 2025Clinical governance standard for telehealthLive
New Priceline Pharmacy appFY2026Omnichannel and loyalty integrationLive
MediAesthetics simplificationFY2025–FY2026Simplified operating model, refreshed brand identities, AestheticsRX expansionProfitable growth in FY2026
Fulfilment centre automationFY2025–FY2027Cairns (operational FY26), Adelaide and Perth (FY27)In progress
Infinity Pharmacy Group interventionDec 2025Receivers appointed to protect wholesale receivables and maintain network continuitySale process ongoing (WES FY26 Results)
Inventory contingency2H FY2026Higher stock to guard against Middle East supply disruptionTemporary working-capital investment
Pulse RewardsAug 2026Sister Club relaunched as a coalition loyalty program across Health brandsLive
Retail media and OnePass integrationOngoingGroup retail media network (OneReach); OnePass benefits extendedScaling
Health screening partnershipsAug 2026Health Check program with SiSU stations; reported involvement of Latrobe Health ServicesDetails limited

Cost programs. Productivity and automation are cited, but no quantified divisional cost-out target has been publicly disclosed.

Medium-term financial targets. Wesfarmers does not publish numerical divisional targets for Health. The qualitative guidance is to "continue improving earnings and returns". Group FY2027 net capex guidance is A$1.3–1.5bn, which includes Health supply-chain investment (WES FY26 Results).

Products & Services

Consumer — Priceline

OfferingDescriptionTarget customerLaunch / latestPricing modelFlagship / notes
Priceline Pharmacy (franchise)Full-service community pharmacy combining dispensary with large health, beauty, cosmetics and personal-care front of shop; pharmacist services such as vaccinations, health checks and dose administration aidsWomen-skewed health and beauty shoppers; prescription patientsFranchise model since the 2000s; 433 stores at 30 June 2026Franchise fees and wholesale supply; retail pricing set by franchisees with API promotionsFY2026 headline network sales +12.7% incl. dispensary; 1H FY26 +14.4%; FY25 +11.9% (WES releases; Pharmacy Daily)
Priceline (company-owned)Non-pharmacy health and beauty storesBeauty and personal-care shoppers67 stores incl. atomica at 30 June 2026, down from 89 in 2022RetailNetwork rationalised since COVID-era closures
atomicaAffordable, accessible beauty-focused retail formatValue-seeking beauty shoppersLaunched January 2025; 10 stores at 30 June 2026RetailPositioned as an addressable-market expansion format (WES FY26 Results)
Pharmacy 4 LessDiscount pharmacy bannerPrice-sensitive shoppersAcquired 4 June 2025 (53 franchised pharmacies plus 12 Your Chemist Shop)Banner/franchiseNamed as a new-format growth lever in FY27 outlook
Soul Pattinson ChemistBanner for independent pharmaciesIndependent pharmacy owners and their patientsLegacy API bannerBanner membershipIncluded in 152 banner pharmacies
Pharmacist AdviceBanner/marketing program for independentsIndependent pharmaciesLegacy API bannerBanner membershipIncluded in 152 banner pharmacies
Club PremiumIndependent pharmacy support program (historic)IndependentsLegacyProgram membershipCited in API's listed-era reporting
InstantScripts Pharmacy Health HubPharmacy format integrating telehealth services in storePatients seeking convenient primary carePilot launched around July 2024; 4 stores at 30 June 2026FranchiseCounted within Priceline Pharmacy
Priceline Pharmacy app and onlineE-commerce, click-and-collect, home delivery, medication management, e-scriptsOmnichannel shoppersNew app launched FY2026Retail"Digital sales grew strongly" in FY26 (WES FY26 Results)
Sister Club → Pulse RewardsLoyalty program; Pulse Rewards is a coalition across Wesfarmers Health brandsAll Health customersSister Club: 9.6m (FY25), more than 10.4m (FY26); Pulse Rewards launched August 2026Free membership; pointsIntegrated with OnePass and Flybuys ecosystem
Private-label and exclusive brandsHealth, vitamins, personal care, skincare and cosmetics rangesPriceline shoppersOngoingRetailExamples include New Zealand brand Daily Skincare ranged in about 400 Priceline stores (Inside FMCG)
Retail mediaSupplier-funded advertising across Priceline assets, linked to Group OneReachSuppliers / brandsScaling FY2025–FY2027Advertising fees—
Health Check programIn-store health screening; reported links to Latrobe Health Services and SiSU stationsPharmacy customersReported August 2026Free/partner-fundedDetails only partially reported (Pharmacy Daily, 19 Aug 2026)

Consumer — MediAesthetics

OfferingDescriptionTarget customerLaunch / latestPricingNotes
SILK Laser ClinicsLaser hair removal, skin treatments and cosmetic injectables; company-owned, franchise and JV clinicsAesthetics consumers (predominantly women, 20–50)Acquired 2023Per-treatment, packages, membershipsPart of 180 clinics at 30 June 2026
Clear Skincare ClinicsLaser, skin and injectables clinicsMass-market aesthetics consumersAcquired by API c.FY2018/19; FY19 revenue A$45.6mPer-treatment, membershipsPulse Rewards materials reference "Australia Skin Clinics", which may indicate a brand refresh. This is not confirmed; the FY26 Results still name Clear Skincare
AestheticsRXPremium cosmeceutical own-brand rangeClinic clientsExpanded FY2026RetailCited as a driver of profitable growth in FY26 (WES FY26 Results)

Network trend. Clinic numbers fell from 219 (FY2024) to 192 (FY2025) to 180 (FY2026). This reflects a "simplified operating model" and closure of 12 clinics in FY2026 (WES FY26 Results).

Consumer — Digital Health

OfferingDescriptionTarget customerLaunch / latestPricingNotes
InstantScriptsTelehealth: online doctor consults, scripts for more than 300 medicines, medical certificates, referralsTime-poor and regional patientsFounded 2017; acquired July 2023 (approx. A$135m)Per-consult feesMore than 1m patient interactions in the year before acquisition (Business News Australia); "growth in users and services" in FY26
SiSU HealthSelf-service health check stations (blood pressure, BMI and similar) in pharmacies and retailGeneral publicStake increased to 60% in FY2023Free to user; sponsor/partner fundedIncluded in acquisition amortisation (WES FY26 Results)
Telehealth Code of PracticeInternal clinical safety and quality frameworkPatients and regulatorsJuly 2025Not applicableGovernance differentiator

Wholesale

OfferingDescriptionCustomerLatestPricingNotes
Full-line pharmaceutical distributionPBS and non-PBS prescription medicines, CSO supplyMore than 4,000 pharmaciesOngoingRegulated PBS wholesale mark-up plus CSO funding shareGrowth from new customers and GLP-1/high-value drugs (FY26)
OTC and front-of-shop supplyOTC medicines, health, beauty and general merchandisePharmaciesOngoingTrade pricing and rebates—
Online B2B hubOrdering platform with "enhanced functionality" for wholesale pharmacy customersMore than 4,000 pharmacies—Not applicableInside FMCG
Automated fulfilment networkAutomation upgrades; new Cairns centre (FY26); Adelaide and Perth centres opening FY2027Internal / customersFY2026–FY2027Not applicableLower supply-chain unit costs in FY26
Franchisee financial supportTrade credit and support facilities to franchiseesPriceline franchiseesOngoing—Exposure crystallised with Infinity in December 2025

Financial Narrative

Because API is a wholly owned subsidiary, it no longer publishes standalone statutory accounts to the market. This section presents three views:

6A: Wesfarmers Health divisional data for FY2022–FY2026, the best available proxy for API's current economics.

6B: API's last listed-era figures for FY2017–FY2021, for history.

6C: Wesfarmers Group consolidated data, for balance sheet, cash-flow and credit context, since debt and equity sit at group level.

6A. Wesfarmers Health — income statement and returns

Source: WES FY26 Results, Divisional key performance metrics.

Notes:

  • Gross profit, net income, EPS and dividends are not publicly disclosed at divisional level.

  • FY2022 and FY2023 EBIT are derived as EBITDA plus D&A; FY2025 and FY2026 EBIT are reported.

  • Margins are computed.

  • Implied capital employed is derived as EBT divided by ROC and is an analyst estimate only.

Revenue CAGR, FY2023–FY2026 (three full years): approximately 6.8%. Computed as (6,474 / 5,312)^(1/3) − 1.

Commentary.

Revenue: Growth accelerated from 5.5% in FY2025 to 9.1% in FY2026. Three drivers are cited in WES FY26 Results:

  • Priceline Pharmacy network expansion (+25 opened / −12 closed franchise stores in FY2026)

  • strong dispensary and retail growth, with headline network sales +12.7%

  • wholesale customer wins and high-value drug volumes, notably GLP-1 weight-loss medications

FY2023 revenue was flattered by more than A$300m of COVID-19 antiviral sales (Wesfarmers 2023 Annual Report, per Pharmacy Daily). This makes FY2024's 5.9% growth on an underlying basis stronger than it appears.

Profitability: EBITDA has risen in each full year, from A$124m to A$168m (+35% over three years), but margins remain razor-thin. The EBITDA margin expanded only 26 basis points between FY2023 and FY2026. The real progress is in EBT, which rose from A$45m to A$76m (+69%), as acquisition amortisation rolls off and operating leverage emerges. EBT growth (18.8%) outpaced revenue growth (9.1%) in FY2026, which is the first clear evidence of the operating leverage management has promised.

Rising lease costs: Lease interest climbed from A$5m to A$12m between FY2024 and FY2026. This reflects new fulfilment centres (Cairns) and store and clinic leases, and is a modest drag that will grow as Adelaide and Perth open.

Returns: ROC of 4.2% in FY2026 is well below Wesfarmers' cost of capital and far below Bunnings (69.2%) and Kmart (68.3%). It is the division's central strategic weakness. Implied capital employed has grown to approximately A$1.8bn through the InstantScripts, SILK, SiSU and Pharmacy 4 Less acquisitions and working capital. FY2026 inventory was deliberately raised as a contingency against Middle East supply disruption (WES FY26 Results).

Capex: Capex nearly doubled from A$38m (FY2024) to A$70m (FY2026), driven by fulfilment automation and new centres. This is consistent with the FY2027 plan to open Adelaide and Perth centres.

6A(ii). Wesfarmers Health — operating KPIs

Sources: WES FY26 Results; Pharmacy Daily for FY2025 network sales growth and Sister Club membership.

6B. API standalone — last five listed fiscal years

These figures come from mixed primary and secondary sources. Where sources conflict, the discrepancy is noted below the table.

Commentary. API's last five listed years show a business with flat revenue of about A$4.0bn and volatile, declining statutory earnings:

PBS price disclosure reforms: steadily eroded wholesale revenue per script.

COVID-19 (FY2020–FY2021): hit Priceline's high-margin cosmetics and cold-and-flu categories. Front-of-shop like-for-like sales fell almost 6% in FY2020, and company stores and the Clear Skincare clinics closed during lockdowns.

Impairments and restructuring: (A$9.4m in October 2020) pushed statutory results to a loss in FY2020 and near break-even in FY2021.

Underlying NPAT guidance for FY2020 was about A$30–31m, roughly 45% below the FY2017 peak of A$54.2m. This deterioration explains why API traded at a depressed valuation of about A$1.15 before the July 2021 approach, and why the A$1.55 offer carried a 35.4% premium.

6C. Wesfarmers Group — consolidated context

Source: WES FY26 Results, Five-year financial performance.

Net margin, ROA and net debt to equity are computed.

Group credit metrics (FY2026).

  • Debt to EBITDA (including leases, ex significant items): 1.9x, versus 1.7x in FY2025.

  • Net financial debt: A$5,295m.

  • Weighted average cost of debt: 3.75%.

  • Committed undrawn facilities: A$1,725m.

Ratios requested but not available at API/Health level. The following are not publicly disclosed for API or Wesfarmers Health and are therefore not estimated:

  • ROE and ROA for the division

  • ROIC (ROC of 4.2% is the closest proxy)

  • current ratio

  • division-level debt/equity, net debt/EBITDA and interest coverage

  • asset turnover

  • cash conversion cycle

Division-level asset turnover can be approximated as revenue divided by implied capital employed, at approximately 3.6x in FY2026 (6,474 / approx. 1,810). This is an analyst estimate.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Internal Business Details

Internal businessContentsKey products / services

Consumer

Priceline (Priceline Pharmacy franchise network, company-owned Priceline and atomica stores, banner brands); MediAesthetics (SILK Laser Clinics, Clear Skincare Clinics, AestheticsRX); Digital Health (InstantScripts, SiSU Health)

Retail health and beauty, dispensary support, clinic treatments, telehealth, health checks, loyalty, retail media

Wholesale (Pharmaceutical Wholesale)

API's national pharmaceutical distribution operation and fulfilment centre network

PBS and non-PBS medicines, OTC and front-of-shop supply to more than 4,000 pharmacy customers; CSO supply

Revenue by Segment and Segment Assets & Liabilities

MetricFY2022FY2023FY2024FY2025FY2026

Wesfarmers Health revenue (AUD Mn)

1,2405,3125,6245,9336,474

Wesfarmers Health EBITDA (AUD Mn)

-2124133150168

Wesfarmers Health EBT (AUD Mn)

-2545506476

Wesfarmers Health EBT ex-PPA amortisation (AUD Mn)

——708292

Wesfarmers Health EBT margin (%)

—0.80.91.11.2

Revenue growth YoY (%)

——5.95.59.1

Health share of Wesfarmers divisional revenue (%)

3.412.212.713.013.7

Revenue by Segment

Metric1H FY20252H FY20251H FY20262H FY2026

Health revenue (AUD Mn)

3,0222,9113,2763,198

Health EBT (AUD Mn)

28363838

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (AUD Mn)

1,2405,3125,6245,9336,474

EBITDA (AUD Mn)

-2124133150168

Depreciation and amortisation (AUD Mn)

-22-74-78-78-80

EBIT (AUD Mn)

-2450557288

Interest on lease liabilities (AUD Mn)

-1-5-5-8-12

EBT (AUD Mn)

-2545506476

Acquisition PPA amortisation included (AUD Mn)

——201816

EBT ex-PPA (AUD Mn)

——708292

EBITDA margin (%)

—2.332.362.532.59

EBIT margin (%)

—0.940.981.211.36

EBT margin (%)

—0.80.91.11.2

Return on capital R12 (%)

—4.23.23.84.2

Capital expenditure, cash basis (AUD Mn)

341386270

Implied capital employed (AUD Mn)

—1,0711,5631,6841,810

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Operating Metrics (count) and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Priceline company-owned stores (count)

8976716867

Priceline Pharmacy franchise stores (count)

376390407419433

Banner brand pharmacies (count)

929699161152

MediAesthetics clinics (count)

9592219192180

Total Health network (count)

652654796840832

Priceline Pharmacy headline network sales growth (%)

———11.912.7

Sister Club members (millions)

———9.610.4

Safety TRIFR R12

—6.64.64.64.0

Scope 1 and 2 market-based emissions (ktCO2e)

13.811.610.99.05.3

Income Statement and Operating Metrics (count)

MetricFY2017FY2019FY2020FY2021

Revenue (AUD Mn)

4,0404,0004,0004,010

Underlying EBITDA (AUD Mn)

120.5———

Reported EBITDA (AUD Mn)

117.9———

Reported or underlying EBIT (AUD Mn)

—9456.3—

Underlying NPAT (AUD Mn)

54.2———

Statutory NPAT (AUD Mn)

—56.6-7.91.4

Total assets (AUD Mn)

——1,5401,529.9

Total liabilities (AUD Mn)

——1,089.11,091.1

Total equity (AUD Mn)

——450.9438.8

Operating cash flow (AUD Mn)

——215.571.8

Priceline Pharmacy network stores (count)

462———

Priceline total network sales (AUD Mn)

—2,2002,000—

Cash Flow and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Group revenue (AUD Mn)

36,83843,55044,18945,70047,274

Group EBIT after lease interest (AUD Mn)

3,4163,6443,7534,2104,184

Group NPAT (AUD Mn)

2,3522,4652,5572,9262,874

Group NPAT ex significant items (AUD Mn)

2,3522,4652,5572,6532,874

Basic EPS (A$ cents)

207.8217.8225.7258.0253.4

Ordinary DPS (A$ cents)

180191198206222

Net margin (%)

6.385.665.796.406.08

Total assets (AUD Mn)

27,28626,54627,30927,98128,884

Total liabilities (AUD Mn)

19,30518,26518,72418,79220,907

Net assets / equity (AUD Mn)

7,9818,2818,5859,1897,977

Net debt (AUD Mn)

4,4914,0094,2724,3265,271

Operating cash flow (AUD Mn)

2,3014,1794,5944,5684,272

Net capital expenditure (AUD Mn)

8841,1831,0441,099779

Free cash flow (AUD Mn)

1,1103,6273,2253,4463,992

Return on equity R12 (%)

29.431.431.334.335.5

ROA, NPAT / total assets (%)

8.629.299.3610.469.95

Net debt to equity (x)

0.560.480.500.470.66

Cash realisation ratio ex significant items (%)

5910010510291

Revenue by Region and Revenue by Region (%)

MetricFY2020FY2021

API New Zealand segment revenue (AUD Mn)

47.742.9

API Australia share of revenue (%)

98.898.9

Capital Markets

ItemDetail

Last traded price

A$1.53 (suspension, 22 March 2022)

Takeover consideration

A$1.55 per share (A$1.50 cash plus A$0.05 dividends)

Premium

35.4% to the 9 July 2021 close; 36.8% to the 1-month VWAP

Total consideration

A$774m

Implied EV/Sales

approx. 0.2x FY2021 revenue of A$4.01bn (equity basis; analyst estimate)

Valuation Snapshot

MetricValueSource / basis

Share price (early October 2026)

approx. A$76.5

Derived from Motley Fool (most optimistic target of A$88.80 implies about 16% upside)

5-year share price change

approx. +40%

Motley Fool, October 2026

Market capitalisation

approx. A$87bn

Derived

P/E (FY26 EPS of 253.4c)

approx. 30x

Derived

P/B

approx. 10.9x

Derived (net assets A$7,977m)

EV/Sales

approx. 1.9x

Derived (net financial debt A$5.3bn; excludes leases)

Analyst consensus

Average target A$77.69 (11 analysts)

Motley Fool, October 2026

FY26 ordinary dividend

222c fully franked (interim 102c, final 120c paid 7 October 2026)

WES FY26 Results

FY26 special distribution

A$1.50/share (110c capital return plus 40c special dividend)

WES FY26 Results

Dividend yield

approx. 2.9%

Derived

Credit ratings

Moody's A3 (stable); S&P A- (stable); S&P downside threshold raised to 3.0x debt/EBITDA in July 2026

WES FY26 Results

Buybacks

No active authorisation verified

Not applicable

Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Ordinary DPS (A$ cents)

180191198206222

Basic EPS (A$ cents)

207.8217.8225.7258.0253.4

Analyst Conclusions

Management guidance

Wesfarmers expects Health to "continue improving earnings" by:

  • executing its transformation program

  • accelerating the higher-margin Consumer business

  • building on Wholesale improvements

  • opening the Adelaide and Perth fulfilment centres in FY2027

  • leveraging Pulse Rewards, retail media and new formats (WES FY26 Results)

No numerical divisional guidance is provided.

Bull case

  1. Operating leverage is real. EBT grew 18.8% on revenue growth of 9.1% in FY26, and 1H FY26 earnings rose 35.7%.

  2. Loyalty and data moat. More than 10.4m loyalty members, plus Group data and retail media, can lift Consumer margins.

  3. Structural wholesale tailwinds. GLP-1 and high-value drug growth, combined with automation, could lift Wholesale returns.

Bear case

  1. Returns are structurally low. ROC of 4.2% after four years of ownership and roughly A$1.8bn of capital employed.

  2. Competitive asymmetry. The Sigma–Chemist Warehouse combination has scale, vertical integration and growth of 15.5%.

  3. The franchise model carries hidden credit risk. Infinity exposed API's role as lender of last resort to franchisees.

Catalysts and monitorables (next 12 months)

  • Wesfarmers AGM (29 October 2026) and the Chair transition

  • Infinity Pharmacy Group sale outcome

  • Pulse Rewards adoption metrics

  • Adelaide and Perth fulfilment centre commissioning

  • 1H FY27 results (February 2027): Health margin and ROC

  • PBS and CSO policy changes

  • Any disclosure of the Consumer/Wholesale segment split

Analyst verdict

Australian Pharmaceutical Industries, the ASX-listed wholesaler and Priceline franchisor, ceased to exist as a public company in April 2022. Its business, however, is larger and more strategically important than ever as the engine of Wesfarmers Health.

Under Wesfarmers, API has been rebuilt from a stagnating A$4bn distributor, whose statutory earnings collapsed to near zero in FY2020–21, into a A$6.5bn multi-format health platform spanning pharmacy, aesthetics, telehealth and loyalty. The FY2026 result was the most convincing since the acquisition:

  • revenue up 9.1%

  • EBT up 18.8% to A$76m (A$92m before acquisition amortisation)

  • Priceline Pharmacy network sales up 12.7%

  • loyalty membership above 10 million

The central issue has not changed: economics. An EBT margin of 1.2% and ROC of 4.2% sit far below Wesfarmers' hurdle rates and well below its retail divisions. Wesfarmers has invested heavily in this platform, through the A$774m purchase price, InstantScripts, SILK, SiSU, Pharmacy 4 Less and automated fulfilment. That investment will only be vindicated if Consumer earnings scale faster than Wholesale's low-margin revenue.

The Infinity receivership was a salutary reminder that the franchise model concentrates risk on API's balance sheet. The Sigma–Chemist Warehouse merger has also created a competitor with roughly 1.7 times the revenue and an integrated discount retail engine.

On balance, the trajectory is positive. Momentum is building, management execution is improving, and the parent's balance sheet provides patient capital. But the division remains a "show-me" story. The key test over the next 12–24 months is whether ROC can move decisively toward double digits as new fulfilment capacity, Pulse Rewards and formats like atomica mature.

For Wesfarmers shareholders, Health is not yet a material earnings contributor, at about 2% of divisional earnings. Its significance is optionality, not current value.

Verdict: improving fundamentals, low returns, monitor for margin inflection.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureCompensation

Emily Amos

Managing Director, Wesfarmers Health

Led the division since its formation in 2022; named MD in June 2023 releases and the FY26 results presentation

Not individually disclosed (not a Wesfarmers KMP in sources reviewed)

Richard Pearson

Chief Customer Officer, Wesfarmers Health

Named in June 2025 (Pharmacy 4 Less) and December 2025 (Infinity) communications

—

Corrina Brazel

—

Profiled by Inside FMCG

—

Amanda Lean

General Manager, Corporate Affairs & Sustainability

Named in 2023 release

—

“—” = not publicly disclosed.

Board of Directors

NameRoleNotes

Michael Chaney AO

Chairman (since November 2015)

Retiring at the conclusion of the 2026 AGM (29 October 2026). Former Wesfarmers MD 1992–2005 (Wesfarmers ASX release, 28 August 2025)

Ken MacKenzie

Non-executive director from 1 June 2026; Chair-designate

Former Chairman of BHP Group and CEO of Amcor; stands for election at the 2026 AGM

Rob Scott

Managing Director and CEO

Presented FY2026 results

Sharon Warburton

Non-executive director

Directors' share plan acquisitions, February 2026

Alan Cransberg

Non-executive director

Directors' share plan acquisitions, February 2026

Rt Hon Simon (Bill) English

Non-executive director

Share issue, March 2026

Friedrich (Tom) Oertzen

Disclosed in directors' trading (buy, March 2026)

—

Other directors

Not fully verified in this research

Refer to the Wesfarmers 2026 Annual Report

Board & Management Changes

DateEvent

28 Aug 2025

Chair succession announced: Chaney to retire at the 2026 AGM; Ken MacKenzie named successor

1 Jun 2026

MacKenzie joined the board

29 Oct 2026 (scheduled)

AGM; MacKenzie assumes chair

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnershipNotes

Wholesale

Sigma Healthcare (incl. Chemist Warehouse)

ASX: SIG

FY26 revenue A$10.8bn (+15.5%), first full year post-merger (Pharmacy Daily)

Wholesale

Symbion (EBOS Group)

ASX/NZX: EBO

EBOS FY26 revenue 13.5bn (+9.9%), underlying profit 614m, as reported (reporting currency per EBOS)

Wholesale

CH2 (Clifford Hallam Healthcare)

Private

Secondary full-line wholesaler; financials not disclosed

Wholesale

Independent Pharmacy Cooperative and regional wholesalers

Private

Niche

Pharmacy retail

Chemist Warehouse

Sigma

Discount market leader

Pharmacy retail

TerryWhite Chemmart

EBOS

Claims more than one-third share of pharmacist prescribing (AJP)

Pharmacy retail

Amcal / Guardian / Discount Drug Stores

Sigma (banners)

Banner competitors

Pharmacy retail

Blooms The Chemist, National Pharmacies, Good Price Pharmacy

Various

National Pharmacies won Canstar's 2026 satisfaction award

Beauty retail

Mecca, Sephora (LVMH), Adore Beauty, Woolworths/Coles beauty aisles

Various

Compete with Priceline/atomica front of shop

Aesthetics

Laser Clinics Australia; independent clinics

Private

Compete with SILK/Clear Skincare

Telehealth

Eucalyptus (Juniper, Pilot), Doctors on Demand, other platforms

Private

Compete with InstantScripts

Peer Comparison FY2026

MetricWesfarmers Health (API)Sigma HealthcareEBOS GroupChemist Warehouse (within Sigma)

Revenue

A$6.47bn (FY26)

A$10.8bn (FY26)

13.5bn (FY26, as reported)

Consolidated in Sigma

Revenue growth

+9.1%+15.5%+9.9%

Not applicable

Profit measure

EBT A$76m (1.2% margin)

—

Underlying profit 614m

Not applicable

Recent Developments

--

Company Snapshot

$4,176.8M

Revenue

SWOT Analysis

Strengths

  • Scale. FY26 revenue of A$6.47bn, up 9.1% (WES FY26 Results).
  • Loyalty. Sister Club exceeded 10.4m members, now relaunched as Pulse Rewards (WES FY26 Results; Pharmacy Daily).
  • Network growth. Priceline Pharmacy franchise stores rose from 376 to 433 between FY22 and FY26.
  • Operating leverage emerging. EBT grew 18.8% against revenue growth of 9.1% in FY26.
  • Parent strength. Wesfarmers is rated A3/A- (stable) with A$1.7bn of undrawn facilities.
  • Portfolio breadth. InstantScripts (more than 1m interactions annually at acquisition) and 180 aesthetics clinics.

Weaknesses

  • Low returns. ROC of 4.2% versus Bunnings at 69.2% (WES FY26 Results).
  • Thin margins. EBITDA margin of 2.59%.
  • Clinic network contraction. From 219 to 180 clinics between FY24 and FY26.
  • Franchisee credit exposure. Infinity, with more than A$400m owed to creditors in total, required receivership.
  • Opaque disclosure. No segment split between Consumer and Wholesale.
  • Rising lease interest. From A$5m to A$12m between FY24 and FY26.

Opportunities

  • New formats. atomica and Pharmacy 4 Less named as FY27 growth formats.
  • Wholesale capacity. Adelaide and Perth automated fulfilment centres opening in FY27.
  • GLP-1 and high-value drugs driving wholesale volume (FY26).
  • Coalition loyalty and retail media (Pulse Rewards, OneReach).
  • Pharmacist scope expansion and in-store health services (Health Hubs, SiSU).
  • Consolidation of distressed operators (Pharmacy 4 Less precedent; Infinity process).

Threats

  • Sigma–Chemist Warehouse scale. A$10.8bn revenue growing 15.5%.
  • PBS reform and price disclosure, which historically eroded API revenue.
  • Supply shocks such as the Middle East conflict, which forced inventory build.
  • Specialist beauty competition (Mecca, Sephora).
  • Telehealth regulation risk.
  • Capital competition within Wesfarmers (Mt Holland FID of A$645–715m; Kmart and Officeworks supply chains).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025 (context)Sigma Healthcare–Chemist Warehouse merger completedCreated a vertically integrated competitor with dominant retail scale
20 Feb 2025 (context)Wesfarmers 1H FY25: Consumer earnings growth offset by higher Wholesale supply-chain costsHighlighted the wholesale drag
29 Apr 2025Pharmacy 4 Less Group entered voluntary administrationWholesale customer distress
4 Jun 2025Wesfarmers Health acquired Pharmacy 4 Less (53 pharmacies plus 12 Your Chemist Shop)Discount format; protected supply relationship
1 Jul 2025Group sold Coregas (A$770m)Group portfolio recycling; capital for growth divisions
Jul 2025Telehealth Code of Practice launchedGovernance in a scrutinised telehealth sector
28 Aug 2025FY25: Health revenue A$5,933m (+5.5%), EBT A$64m (+28%); Priceline network sales +11.9%; 31 new stores; Sister Club 9.6mMomentum in Consumer
28 Aug 2025Wesfarmers Chair succession announcedGovernance continuity
30 Oct 2025Wesfarmers AGM approved the capital returnGroup capital management
4 Dec 2025A$1.50/share capital management distribution paid (A$1,703m)Raised Group net debt to A$5.3bn
17 Dec 2025API appointed KPMG receivers and administrators to 56 Infinity pharmacies; Wesfarmers reportedly withdrew a rescue planFranchise-model stress; credit exposure
17–18 Dec 2025Paragon Care disclosed A$46.9m exposure; shares fell 13.5%Industry contagion
Dec 2025 – Jan 2026Priceline statement that the stores are not closing; Infinity operates 92 pharmacies, 72 of them PricelineReputation management
Jan–Feb 2026Commentary on vulnerabilities in the Priceline franchise model (Inside Retail, 21 Jan; Inside FMCG, 4 Feb)Strategic scrutiny
19 Feb 20261H FY26: Health revenue +8.4%, earnings +35.7%; Priceline network sales +14.4%Acceleration
2H FY2026Middle East conflict prompted higher inventory contingency in HealthWorking capital up; operating cash flow down
1 Jun 2026Ken MacKenzie joined the Wesfarmers boardGovernance transition
FY2026Cairns fulfilment centre fully operationalSupply-chain capacity
1 Jul 2026Group: Industrial & Safety moved into BunningsGroup simplification; Health remains a standalone division
22 Jul 2026Group: Mt Holland expansion FID (Wesfarmers share A$645–715m)Capital competition within Group
Aug 2026Sister Club relaunched as Pulse Rewards coalitionLoyalty across Health brands
Aug 2026Health Check program expansion with SiSU stations (reported)Preventive health services
27 Aug 2026FY26: Health revenue A$6,474m (+9.1%), EBT A$76m (+18.8%), ROC 4.2%; Sister Club above 10.4mStrongest result since acquisition
27 Aug 2026Outlook: Adelaide and Perth fulfilment centres to open in FY27; atomica and Pharmacy 4 Less as formats; Infinity sale process progressingForward plan
27 Aug 2026Sigma reported FY26 revenue of A$10.8bn (+15.5%)Competitive benchmark
7 Oct 2026Wesfarmers final dividend of A$1.20 paidShareholder returns
29 Oct 2026 (upcoming)Wesfarmers AGM; MacKenzie to become ChairGovernance event

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit (FY2022–FY2026): Revenue rose from AUD 1,240 Mn in FY2022 to AUD 6,474 Mn in FY2026.
Australian Pharmaceutical Industries Limited — Income Statement: Revenue & Gross Profit (FY2022–FY2026)
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue1,2405,3125,6245,9336,474

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.